Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02644668 · ClinicalTrials.gov registry record · Phase 2
A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
A Phase 2 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02644668: Completed Phase 2 study, sponsored by Cytokinetics.
NCT02644668 is a Phase 2 study that has completed, run by Cytokinetics. The registered enrollment target is 70 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02644668, a Phase 2 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacodynamic (PD) effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on measures of skeletal muscle function or fatigability in patients with Type II, III, or IV spinal muscular atrophy (SMA).
Primary Outcome
FVC was measured using a calibrated spirometer (in units of liters). Patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs).
Interventions
- DRUG Placebo
- DRUG Reldesemtiv 150 mg
- DRUG Reldesemtiv 450 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-01-14 |
| Est. Completion | 2018-05-31 |
| Phase | Phase 2 |
What the finished NCT02644668 record still lists
NCT02644668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02644668 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02644668 about?
NCT02644668 is a clinical study titled "A Study of CK-2127107 in Patients With Spinal Muscular Atrophy". This study will evaluate the pharmacodynamic (PD) effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on measures of skeletal muscle function or fatigability in patients with Type II, III, or IV spinal muscular atrophy (SMA).
What is the current status of trial NCT02644668?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2016-01-14. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT02644668?
The interventions under investigation include: Placebo (DRUG), Reldesemtiv 150 mg (DRUG), Reldesemtiv 450 mg (DRUG).
Who is sponsoring clinical trial NCT02644668?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02644668's enrollment target sits among peer trials
70 937th of 2000 higher than 1,036 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI